Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research

Hsiao Mei Chao, Edward Chern

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Induced pluripotent stem cells (iPSCs) are embryonic stem cell-like cells reprogrammed from somatic cells by four transcription factors, OCT4, SOX2, KLF4 and c-MYC. iPSCs derived from cancer cells (cancer-iPSCs) could be a novel strategy for studying cancer. During cancer cell reprogramming, the epigenetic status of the cancer cell may be altered, such that it acquires stemness and pluripotency. The cellular behavior of the reprogrammed cells exhibits dynamic changes during the different stages of reprogramming. The cells may acquire the properties of cancer stem cells (CSCs) during the process of reprogramming, and lose their carcinogenic properties during reprogramming into a cancer-iPSCs. Differentiation of cancer-iPSCs by teratoma formation or organoid culturing could mimic the process of tumorigenesis. Some of the molecular mechanisms associated with cancer progression could be elucidated using the cancer-iPSC model. Furthermore, cancer-iPSCs could be expanded in culture system or bioreactors, and serve as cell sources for research, and as personal disease models for therapy and drug screening. This article introduces cancer studies that used the cell reprogramming strategy.

Original languageEnglish
Pages (from-to)1046-1057
Number of pages12
JournalJournal of the Formosan Medical Association
Volume117
Issue number12
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Stem Cell Research
Induced Pluripotent Stem Cells
Neoplastic Stem Cells
Neoplasms
SOXB1 Transcription Factors
Organoids
Preclinical Drug Evaluations
Teratoma
Bioreactors
Embryonic Stem Cells
Epigenomics
Carcinogenesis

Keywords

  • Cancer stem cell
  • Cell reprogramming
  • Induced pluripotent stem cells (iPSCs)
  • Tumorigenesis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research. / Chao, Hsiao Mei; Chern, Edward.

In: Journal of the Formosan Medical Association, Vol. 117, No. 12, 01.12.2018, p. 1046-1057.

Research output: Contribution to journalReview article

@article{2d712dc95ed14e2fb03444cf5008d0d8,
title = "Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research",
abstract = "Induced pluripotent stem cells (iPSCs) are embryonic stem cell-like cells reprogrammed from somatic cells by four transcription factors, OCT4, SOX2, KLF4 and c-MYC. iPSCs derived from cancer cells (cancer-iPSCs) could be a novel strategy for studying cancer. During cancer cell reprogramming, the epigenetic status of the cancer cell may be altered, such that it acquires stemness and pluripotency. The cellular behavior of the reprogrammed cells exhibits dynamic changes during the different stages of reprogramming. The cells may acquire the properties of cancer stem cells (CSCs) during the process of reprogramming, and lose their carcinogenic properties during reprogramming into a cancer-iPSCs. Differentiation of cancer-iPSCs by teratoma formation or organoid culturing could mimic the process of tumorigenesis. Some of the molecular mechanisms associated with cancer progression could be elucidated using the cancer-iPSC model. Furthermore, cancer-iPSCs could be expanded in culture system or bioreactors, and serve as cell sources for research, and as personal disease models for therapy and drug screening. This article introduces cancer studies that used the cell reprogramming strategy.",
keywords = "Cancer stem cell, Cell reprogramming, Induced pluripotent stem cells (iPSCs), Tumorigenesis",
author = "Chao, {Hsiao Mei} and Edward Chern",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.jfma.2018.06.013",
language = "English",
volume = "117",
pages = "1046--1057",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research

AU - Chao, Hsiao Mei

AU - Chern, Edward

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Induced pluripotent stem cells (iPSCs) are embryonic stem cell-like cells reprogrammed from somatic cells by four transcription factors, OCT4, SOX2, KLF4 and c-MYC. iPSCs derived from cancer cells (cancer-iPSCs) could be a novel strategy for studying cancer. During cancer cell reprogramming, the epigenetic status of the cancer cell may be altered, such that it acquires stemness and pluripotency. The cellular behavior of the reprogrammed cells exhibits dynamic changes during the different stages of reprogramming. The cells may acquire the properties of cancer stem cells (CSCs) during the process of reprogramming, and lose their carcinogenic properties during reprogramming into a cancer-iPSCs. Differentiation of cancer-iPSCs by teratoma formation or organoid culturing could mimic the process of tumorigenesis. Some of the molecular mechanisms associated with cancer progression could be elucidated using the cancer-iPSC model. Furthermore, cancer-iPSCs could be expanded in culture system or bioreactors, and serve as cell sources for research, and as personal disease models for therapy and drug screening. This article introduces cancer studies that used the cell reprogramming strategy.

AB - Induced pluripotent stem cells (iPSCs) are embryonic stem cell-like cells reprogrammed from somatic cells by four transcription factors, OCT4, SOX2, KLF4 and c-MYC. iPSCs derived from cancer cells (cancer-iPSCs) could be a novel strategy for studying cancer. During cancer cell reprogramming, the epigenetic status of the cancer cell may be altered, such that it acquires stemness and pluripotency. The cellular behavior of the reprogrammed cells exhibits dynamic changes during the different stages of reprogramming. The cells may acquire the properties of cancer stem cells (CSCs) during the process of reprogramming, and lose their carcinogenic properties during reprogramming into a cancer-iPSCs. Differentiation of cancer-iPSCs by teratoma formation or organoid culturing could mimic the process of tumorigenesis. Some of the molecular mechanisms associated with cancer progression could be elucidated using the cancer-iPSC model. Furthermore, cancer-iPSCs could be expanded in culture system or bioreactors, and serve as cell sources for research, and as personal disease models for therapy and drug screening. This article introduces cancer studies that used the cell reprogramming strategy.

KW - Cancer stem cell

KW - Cell reprogramming

KW - Induced pluripotent stem cells (iPSCs)

KW - Tumorigenesis

UR - http://www.scopus.com/inward/record.url?scp=85054172581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054172581&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2018.06.013

DO - 10.1016/j.jfma.2018.06.013

M3 - Review article

AN - SCOPUS:85054172581

VL - 117

SP - 1046

EP - 1057

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 12

ER -